Figure 3
Survival curves of ΔmHLA-DR. Comparison of 28-day mortality by means of Kaplan-Meier survival curves for (a) patients with ΔmHLA-DR3 of greater than 4.8% (continuous line) and ΔmHLA-DR3 of not more than 4.8% (dashed line), (b) patients with ΔmHLA-DR7 of greater than 9% (continuous line) and ΔmHLA-DR7 of not more than 9% (dashed line), and (c) patients with ΔmHLA-DR7-3 of greater than 3.5% (continuous line) and ΔmHLA-DR7-3 of not more than 3.5% (dashed line). ΔmHLA-DR3 and ΔmHLA-DR7 were defined as the value change in mHLA-DR on days 3 and 7 compared with that on day 0, and ΔmHLA-DR7-3 was defined as the value change in mHLA-DR on day 7 compared with that on day 3. mHLA-DR, monocyte human leukocyte antigen-DR.